Nilesh Jethwa: Reported Adverse Events and Safety Signals With Ofatumumab
Nilesh Jethwa, Founder and CEO at InfoCaptor (Rudrasoft), shared a post on X:
“The adverse event reports for ofatumumab indicate a total of 3,291 reports spanning from July 2024 to June 2026.
The most frequently reported adverse events include febrile neutropenia (500 reports), neutropenia (380 reports), and anemia (320 reports). Among the outcomes, 383 reports were classified as Fatal, while many others were categorized as Unknown or Recovered, suggesting a mix of severity in the reported cases.
Serious reactions frequently included febrile neutropenia and neutropenia, indicating these may be significant concerns. There is a notable difference in the sex breakdown, with more reports from males (1,516) compared to females (1,145).
The reporting trend appears to be stable over the recent months, with fluctuations but no clear rising or falling pattern. Additionally, serious-sounding terms such as hemorrhage and thrombocytopenia were also reported.
It is important to note that these adverse event reports are spontaneous and voluntary, do not establish causation, may contain duplicates, and cannot be used to calculate true incidence or risk.”
Stay updated with Hemostasis Today.
-
Oct 17, 2026, 04:07Weihao Li: Global HEPATIC Registry Findings on Post-Transplant Arterial Thrombosis
-
Oct 17, 2026, 03:56Ghaith Abu-Zeinah: ASH Publishes 2026 Guidelines for Myelofibrosis Management in Blood Advances
-
Oct 17, 2026, 03:48Tristan Siokos: Why Vascular Occlusion Is More Than Just Clots – Breakdown of the 8 Pathways
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries
-
Oct 17, 2026, 02:35Carly Newton: Understanding Access to Red Blood Cell Exchange for People Living With SCD
-
Oct 17, 2026, 02:34Raising Awareness of Blood Clots During and After Pregnancy – Thrombosis UK
-
Oct 17, 2026, 02:33Alaa Salamat: Our Research Accepted for Publication at ASH 2026
-
Oct 17, 2026, 02:32Mohammed Al Sharif: Discussing Factor XIII Testing and Its Clinical Significance
-
Oct 17, 2026, 02:31Joanna Popiolek-Kalisz: Talking about Novel Pharmacotherapy for Hypertension at CV Prevention and Intervention